0001562180-22-007176.txt : 20221012 0001562180-22-007176.hdr.sgml : 20221012 20221012183129 ACCESSION NUMBER: 0001562180-22-007176 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221003 FILED AS OF DATE: 20221012 DATE AS OF CHANGE: 20221012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coric Vlad CENTRAL INDEX KEY: 0001704317 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41477 FILM NUMBER: 221307669 MAIL ADDRESS: STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP STREET 2: 234 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Ltd. CENTRAL INDEX KEY: 0001935979 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 FORMER COMPANY: FORMER CONFORMED NAME: Biohaven Research Ltd. DATE OF NAME CHANGE: 20220629 4/A 1 primarydocument.xml PRIMARY DOCUMENT X0306 4/A 2022-10-03 2022-10-05 false 0001935979 Biohaven Ltd. BHVN 0001704317 Coric Vlad C/O BIOHAVEN LTD. 215 CHURCH STREET NEW HAVEN CT 06510 true true false false Chief Executive Officer Common Shares 2022-10-03 4 J false 0.00 0.00 A 569309.00 D Effective as of the pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares pursuant to the Separation and Distribution Agreement, dated as of May 9, 2022, by and among RemainCo, the Issuer and Pfizer Inc. ("Pfizer"), each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. (Cont'd in FN2) (Cont'd from FN1) As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares. This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 105,950 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares; however, as reflected in this amendment, 52,975 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. There were no other changes made to the information in the Original Form 4. /s/ George Clark, Attorney-in-Fact 2022-10-12